Abstract Background: Radiopharmaceuticals have emerged as an important therapeutic strategy, but their evaluation in preclinical models is limited by the radiosensitivity of commonly used immunodeficient mice. The B-NDG mice (NOD.CB17-Prkdcscid Il2rgtm1Bcgen/Bcgen), generated via Prkdc mutation, lack mature T and B cells but are hypersensitive to DNA damage due to impaired DNA repair, leading to rapid body weight loss and mortality under irradiation. Methods: To overcome these limitations, Biocytogen developed the B-CDG mice on a C57BL/6 background by knocking out Rag2 and Il2rg. This strain lacks mature T, B, and NK cells but retains normal DNA repair capability. Comparative analyses of B-CDG mice and B-NDG mice were performed under X-ray irradiation at doses of 1, 2.5, 4, and 7 Gy. Survival, body weight, hematology, and histopathology were assessed. Additionally, multiple human tumor cell lines—LNCap Clone FGC, 22Rv1, BT-474, AsPC-1, and SHP-77—were tested for xenograft formation. Results: B-CDG mice demonstrated superior tolerance to radiation. At 1 Gy and 2.5 Gy, all B-CDG mice survived 30 days, while all B-NDG mice exposed to ≥2.5 Gy died within 2 days. At 4 Gy, partial survival was observed in B-CDG mice, with recovery of body weight after initial decline. Hematology revealed dose-dependent decreases in leukocytes, erythrocytes, and platelets, with subsequent recovery at 30 days. Histological analysis showed extramedullary hematopoiesis in the liver and spleen of B-CDG mice, milder cellular injury, and compensatory marrow regeneration compared to B-NDG mice. Moreover, all tested tumor cell lines successfully established xenografts in B-CDG mice. Conclusion: B-CDG mice are a novel severe immunodeficient strain that maintains DNA repair competence and radiation tolerance. These characteristics make B-CDG mice an ideal platform for evaluating the efficacy and toxicity of radiopharmaceuticals and other DNA-damaging agents. Citation Format: Qiurong Wang, Yanhui Nie, Ruili Lv, Chengzhang Shang, Meiqi Zhang, Qingqing Xu. B-CDG mice: A novel severe immunodeficient model suitable for radiotherapeutic and radiopharmaceutical evaluation abstract. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 6976.
Building similarity graph...
Analyzing shared references across papers
Loading...
Qiurong Wang
Yanhui Nie
Ruili Lv
Cancer Research
Beijing Biocytogen (China)
Building similarity graph...
Analyzing shared references across papers
Loading...
Wang et al. (Fri,) studied this question.
www.synapsesocial.com/papers/69d1fceba79560c99a0a29de — DOI: https://doi.org/10.1158/1538-7445.am2026-6976